ethyl (E)-2-methoxyimino-3-oxobutanoate | 66340-41-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: ethyl (E)-2-methoxyimino-3-oxobutanoate
• 英文别名: 2,3-Dioxobutyric acid 2-methyloxime ethyl ester；ethyl (2E)-2-methoxyimino-3-oxobutanoate
• CAS: 66340-41-8
• 化学式: C₇H₁₁NO₄
• 分子量: 173.169
• InChiKey: HASOOENYFDJEAK-SOFGYWHQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  65
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl (E)-2-methoxyimino-3-oxobutanoate 以10%的产率得到
  参考文献：
  名称：

  MARKOV V. I.; PROSYANIK A. V.; MISHCHENKO A. I., VOPR. XIMII I XIM. TEXNOL. (XARKOV), 1980, HO 58, 90-100

  摘要：

  DOI：
• 作为产物：
  描述：

  (E)-ethyl 2-(hydroxyimino)-3-oxobutanoate 生成 ethyl (E)-2-methoxyimino-3-oxobutanoate
  参考文献：
  名称：

  TAKAYA, TAKAO;TAKASUGI, HISASHI;CHIBA, TOSHIYUKI;TOZUKA, ZENZABURO

  摘要：

  DOI：

文献信息

• CONJUGATED ANTI-MICROBIAL COMPOUNDS AND CONJUGATED ANTI-CANCER COMPOUNDS AND USES THEREOF
  申请人：PONO CORPORATION

  公开号：US20150150995A1

  公开（公告）日：2015-06-04

  Disclosed herein are synthesis methods for generation of conjugated anti-microbial compounds and conjugated anti-cancer compounds. Several embodiments, related to the uses of such compounds in the treatment of infections, in particular those caused by drug-resistant bacteria. Some embodiments relate to targeting cancer based on the metabolic signature of tumor cells.

  本文公开了合成共轭抗微生物化合物和共轭抗癌化合物的方法。其中几种实施例与上述化合物在治疗感染方面的应用有关，特别是那些由耐药细菌引起的感染。一些实施例涉及基于肿瘤细胞代谢特征的癌症治疗。
• Mechanistic Insights into the Ene-Reductase-Catalyzed Promiscuous Reduction of Oximes to Amines
  作者：Willem B. Breukelaar、Nakia Polidori、Amit Singh、Bastian Daniel、Silvia M. Glueck、Karl Gruber、Wolfgang Kroutil

  DOI：10.1021/acscatal.2c06137

  日期：2023.2.17

  transforming α-oximo β-keto esters. However, the reaction pathway of this two-step reduction remained elusive. By studying the crystal structures of enzyme oxime complexes, analyzing molecular dynamics simulations, and investigating biocatalytic cascades and possible intermediates, we obtained evidence that the reaction proceeds via an imine intermediate and not via the hydroxylamine intermediate. The

  直到最近才发现将肟部分生物催化还原为相应的胺基是转化 α-肟基 β-酮酯的烯还原酶的混杂活性。然而，这种两步还原的反应途径仍然难以捉摸。通过研究酶肟复合物的晶体结构、分析分子动力学模拟以及研究生物催化级联和可能的中间体，我们获得了反应通过亚胺中间体而不是通过亚胺进行的证据羟胺中间体。亚胺被烯还原酶进一步还原成胺产物。值得注意的是，发现非典型酪氨酸残基有助于烯还原酶 OPR3 的催化活性，在第一步还原中使肟的羟基质子化。
• Starting compounds for preparing cephem compounds and processes for their preparation
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0009671A2

  公开（公告）日：1980-04-16

  Compounds of formula (I) are used in the preparation of cephalosporins of formula (II) which are precursors of cephalosporins of formula (III) which show a pharmacological activity: wherein: X' = hydrogen or halogen A1, A2 = acetal residue which may be linked together R, = aliphatic hydrocarbon group which may have suitable substituents Y' = carbonyl or protected carbonyl group R2 = carboxyl or protected carboxyl group R. = hydroxy, acyloxy or methylene

  式(I)化合物用于制备式(II)头孢菌素，而式(II)头孢菌素是具有药理活性的式(III)头孢菌素的前体： 其中 X' = 氢或卤素 A1、A2 = 可连接在一起的缩醛残基 R, = 脂肪族烃基，可带有合适的取代基 Y' = 羰基或受保护的羰基 R2 = 羧基或受保护的羧基 R. = 羟基、酰氧基或亚甲基
• Intermediate compounds for preparing cephem compounds; processes for their preparation and processes for preparing cephem compounds
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0048504A2

  公开（公告）日：1982-03-31

  New intermediate compounds for preparing cephem compounds, particularly of the formula or its salt. The new intermediate compounds can be prepared by different processes, and the cephem compounds, which possess valuable pharmacological properties, can be prepared from such new intermediate compounds.

  用于制备头孢化合物的新型中间体化合物，特别是式 或其盐。新的中间体化合物可以通过不同的工艺制备，而具有重要药理特性的头孢氨苄化合物则可以从这些新的中间体化合物中制备出来。
• Vinyl-glycyl-amino-beta-lactam derivatives
  申请人：BEECHAM GROUP PLC

  公开号：EP0209237A2

  公开（公告）日：1987-01-21

  β-Lactam antibiotics are disclosed having the partial structure: where R1 is: in which R2, R3 and R4 are the same or different and each is hydrogen; halogen; optionally substituted C1-6 alkyl; optionally substituted C3-7 cycloalkyl; optionally substituted C2-6 alkenyl; optionally substituted C2-6 alkynyl; amido; cyano; carboxy; formyl; C1-6 alkoxycarbonyl; mono- or di-(C1-6)alkylamido; C1-6 alkylcarbonyl; an aryl group; a heterocyclyl group; or R3 and R4 are joined together to form the residue of a carbocyclic ring having a total of from 3 to 7 carbon atoms in the ring; or R3 and R4 are joined together to form the residue of a heterocyclic ring in which R3 and R4 together may be represented by the formula -(CH2)mX(CN2)n in which X is oxygen, sulphur or a group NR5 wherein R5 is hydrogen, acyl, an amino-protecting group, or C1-6 alkyl, m is 1 to 3 and n is 1 to 3; and also the use thereof. Processes for the preparation of the compounds are disclosed together with intermediates for use therein.

  β-内酰胺类抗生素具有以下部分结构： 其中R1为 其中R2、R3和R4相同或不同，且各自为氢；卤素；任选取代的C1-6烷基；任选取代的C3-7环烷基；任选取代的C2-6烯基；任选取代的C2-6炔基；氨基；氰基；羧基；甲酰基；C1-6烷氧基羰基；单-或 二-(C1-6)烷基氨基；C1-6 烷基羰基；芳基；杂环基；或 R3 和 R4 连接在一起形成碳环的残基，环中共有 3 至 7 个碳原子；或 R3 和 R4 连接在一起形成杂环的残基，其中 R3 和 R4 可由式-(CH2)mX(CN2)n 表示，式中 X 是氧、硫或基团 NR5，其中 R5 是氢、酰基、氨基保护基团或 C1-6 烷基，m 是 1 至 3，n 是 1 至 3；以及其用途。 公开了这些化合物的制备工艺及其使用的中间体。